KNSAKiniksa Pharmaceuticals International, plc
Pharmaceutical Preparations
- Revenue
- $678M
- 60% YoY
- Operating margin
- 11.4%
- 206% YoY
- EBITDA
- $79M
- 279% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear234% of net incomeCash flow under 80% of net income
- Dilutive SBCClear5% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $39M | $220M | $270M | $423M | $678M | 60% |
| Operating income | −$157M | $10M | −$25M | −$46M | $77M | 269% |
| Net income | −$158M | $183M | $14M | −$43M | $59M | 237% |
| Operating cash flow | −$126M | $6M | $13M | $26M | $138M | 437% |
| Capex | $415K | $105K | $130K | $277K | $2M | 466% |
| Stock-based comp | $25M | $25M | $27M | $31M | $37M | 21% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $11M | $28M | 233 | 125 |
| FY2024 | $7M | $9M | 112 | 91 |
| FY2023 | $5M | $7M | 99 | 92 |
| FY2022 | $6M | $9M | 85 | 89 |
| FY2021 | $7M | $579K | 67 | 99 |